



Bio-Works Technologies AB - Business Update first quarter 2026

Net Sales:	MSEK	Compare
First quarter 2026	29,3	(9,0)
Last two quarters	53,0	(11,6)
Last four quarters	82,8	(28,5)

Order intake:	MSEK	Compare
First quarter 2026	15,5	(31,6)

Order-book on 2026-03-31 17,7

The sales and order figures for the first quarter above are preliminary. We would like to remind that sales and order intake may vary significantly between quarters as we are still in a growth phase.

This update is made in accordance with a decision by the board of Bio-Works Technologies AB as of Q4 2025 to report sales, orderbook and order intake immediately after the end of each quarter. The purpose is to provide owners and investors with faster information and a better overview of the company's development.

Contacts

For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works

Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.